Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritisPhilip J. Mease, Subhashis Banerjee, Désirée van der Heijde et al.|Annals of the Rheumatic Diseases|2022Cited by 212